A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Capricor Therapeutics, Inc. is a biotechnology company focused on the development and potential commercialization of cell and exosome-based therapeutics for the treatment of Duchenne muscular dystrophy (“DMD”), a rare genetic disorder characterized by progressive muscle degeneration and premature death, as well as other diseases with significant unmet medical need. Since our inception, we have devoted substantial resources to the development of our lead product candidate, Deramiocel, a cell therapy designed to address the cardiac and skeletal muscle complications associated with DMD, as well as to advancing our exosome-based platform, developing manufacturing capabilities and supporting our research and development activities. Our Biologics License Application (“BLA”) for Deramiocel for the treatment of DMD is currently under review by the U.S.
| Segment | 2024 | % of Total |
|---|---|---|
Single reportable segment | $22M | 100% |
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 22M | 25M | - | - |
| Net Income | -105M | -105M | -40M | -22M | -29M | -20M |
| EPS | $-2.26 | $-2.26 | $-1.15 | $-0.83 | $-1.18 | $-0.87 |
| Free Cash Flow | -73M | -73M | -41M | -27M | 2.9M | -18M |
| ROIC | -263.1% | -46.6% | -27.8% | -98.6% | -191.4% | -57.6% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.05 | 0.05 | 0.01 | 0.10 | 0.50 | 0.20 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -108M | -108M | -43M | -24M | -30M | -21M |
| Operating Margin | 0.0% | - | -191.1% | -95.6% | - | - |
| ROE | -34.4% | -46.6% | -27.8% | -98.6% | -246.2% | -63.8% |
| Shares Outstanding | 46M | 46M | 35M | 27M | 25M | 23M |
CAPRICOR THERAPEUTICS, INC. passes 0 of 9 quality checks, indicating weak fundamentals.
At current prices, the estimated annualized return to fair value is -11.0%.
CAPRICOR THERAPEUTICS, INC. (CAPR) has a 5-year average return on invested capital (ROIC) of -84.4%. This is below average and may indicate limited pricing power.
CAPRICOR THERAPEUTICS, INC. (CAPR) has a market capitalization of $1.6B. It is classified as a small-cap stock.
CAPRICOR THERAPEUTICS, INC. (CAPR) does not currently pay a regular dividend.
CAPRICOR THERAPEUTICS, INC. (CAPR) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
CAPRICOR THERAPEUTICS, INC. (CAPR) generated $-73 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
CAPRICOR THERAPEUTICS, INC. (CAPR) has a debt-to-equity ratio of 0.05. This indicates a conservatively financed balance sheet.
CAPRICOR THERAPEUTICS, INC. (CAPR) reported earnings per share (EPS) of $-2.26 in its most recent fiscal year.
CAPRICOR THERAPEUTICS, INC. (CAPR) has a return on equity (ROE) of -46.6%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 15 years of financial data for CAPRICOR THERAPEUTICS, INC. (CAPR), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
CAPRICOR THERAPEUTICS, INC. (CAPR) has a book value per share of $6.58, based on its most recent annual SEC filing.